Optimized size exclusion chromatography demonstrates that extracellular vesicles are the key RNA carriers of ALK translocations in non-small cell lung cancer cell line secretome and patient plasma

Abstract

Aim: Identification of ALK fusions in non-small cell lung cancer (NSCLC) is key to determining eligibility for treatment with ALK inhibitors that markedly improve patients’ quality of life and survival outcomes. Circulating RNA, associated with various carriers including extracellular vesicles (EVs), lipoproteins (LPPs), or protein complexes, presents a viable target for the identification of ALK fusions by liquid biopsy. Our aim was to characterize the specific carrier of ALK fusion RNA, a crucial step in the development of diagnostic methods for clinical use.

Methods: We employed optimized size-exclusion chromatography (SEC) to separate EVs, LPPs, and protein-enriched fractions from ALK-positive NSCLC cell lines and from pools of plasma obtained from NSCLC patients with ALK translocations. We optimized RNA fusion transcript detection using digital PCR (dPCR).

Results: Protein analyses confirmed the successful resolution of EVs, LPPs, and protein fractions by optimized SEC. Our dPCR results indicated that ALK fusions were more prevalent in tetraspanin-enriched SEC fractions from NSCLC cell lines, suggesting that EVs serve as the primary carrier for ALK fusion RNA. After optimization for larger volumes of samples of the RNA isolation protocol, we could also demonstrate that ALK fusion transcripts were found exclusively in EVs from patient plasma. Of note, the circulating number of copies of the transcript was below 5 copies/mL.

Discussion: Our findings underscore the potential of EV-associated RNA as a promising source for detecting ALK fusion variants in plasma samples from NSCLC patients, offering a non-invasive diagnostic approach with significant clinical implications.

Keywords

Non-small-cell lung cancer / extracellular vesicles / ALK / size-exclusion chromatography / liquid biopsy

References

[1] Travis WD, Brambilla E, Nicholson AG, et al; WHO Panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243-60.

[2] Barlesi F, Mazieres J, Merlio JP, et al; Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415-26.

[3] Ettinger DS,Aisner DL.Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2022;20:497-530

[4] Sánchez-Herrero E,Romero A.Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients.Adv Lab Med2020;1:20190019 PMCID:PMC10197761

[5] Soda M,Enomoto M.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature2007;448:561-6

[6] Sasaki T,Chirieac LR.The biology and treatment of EML4-ALK non-small cell lung cancer.Eur J Cancer2010;46:1773-80 PMCID:PMC2888755

[7] Camidge DR,Ahn MJ.Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer.N Engl J Med2018;379:2027-39

[8] Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018-29.

[9] Gerlinger M,Horswell S.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med2012;366:883-92

[10] Heidrich I,Mossahebi Mohammadi P.Liquid biopsies: potential and challenges.Int J Cancer2021;148:528-45

[11] Alix-Panabières C.Liquid biopsy: from discovery to clinical application.Cancer Discov2021;11:858-73

[12] Cescon DW,Chan SM.Circulating tumor DNA and liquid biopsy in oncology.Nat Cancer2020;1:276-90

[13] Vickers KC,Shoucri BM,Remaley AT.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nat Cell Biol2011;13:423-33 PMCID:PMC3074610

[14] Rossi-Herring G,Rivas-Urbina A.Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile.Biomed Pharmacother2023;162:114623

[15] Allen RM,Cavnar AB.LDL delivery of microbial small RNAs drives atherosclerosis through macrophage TLR8.Nat Cell Biol2022;24:1701-13 PMCID:PMC10609361

[16] Arroyo JD,Kroh EM.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.Proc Natl Acad Sci U S A2011;108:5003-8 PMCID:PMC3064324

[17] Yáñez-Mó M,Andreu Z.Biological properties of extracellular vesicles and their physiological functions.J Extracell Vesicles2015;4:27066 PMCID:PMC4433489

[18] Fais S,Borras FE.Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine.ACS Nano2016;10:3886-99

[19] Reclusa P,Malapelle U.EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy.Transl Cancer Res2019;8:S76-8 PMCID:PMC8798325

[20] Sánchez-Herrero E,Cáceres-Martell Y.ALK-fusion transcripts can be detected in extracellular vesicles (EVs) from nonsmall cell lung cancer cell lines and patient plasma: toward EV-based noninvasive testing.Clin Chem2022;68:668-79

[21] Stranska R,Wouters J.Comparison of membrane affinity-based method with size-exclusion chromatography for isolation of exosome-like vesicles from human plasma.J Transl Med2018;16:1 PMCID:PMC5761138

[22] Cvjetkovic A,Lässer C.The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles.J Extracell Vesicles2014;3:23111 PMCID:PMC3967015

[23] Benayas B,Egea C,Yáñez-Mó M.Optimization of extracellular vesicle isolation and their separation from lipoproteins by size exclusion chromatography.J Extracell Biol2023;2:e100 PMCID:PMC11080862

[24] López-Guerrero JA,Borrás FE,Vicent MJ.Standardising the preanalytical reporting of biospecimens to improve reproducibility in extracellular vesicle research - a GEIVEX study.J Extracell Biol2023;2:e76 PMCID:PMC11080825

[25] Levy S,Maecker HT.CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.Annu Rev Immunol1998;16:89-109

[26] Yáñez-Mó M,Cabañas C.Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with α3β1 integrin localized at endothelial lateral junctions.J Cell Biol1998;141:791-804 PMCID:PMC2132738

[27] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[28] Prieto-Vila M,Ochiya T.Biological functions driven by mRNAs carried by extracellular vesicles in cancer.Front Cell Dev Biol2021;9:620498 PMCID:PMC8435577

[29] Villarroya-Beltri C,Gutiérrez-Vázquez C,Mittelbrunn M.Sorting it out: regulation of exosome loading.Semin Cancer Biol2014;28:3-13 PMCID:PMC4640178

[30] Wei Z,Schinelli S.Coding and noncoding landscape of extracellular RNA released by human glioma stem cells.Nat Commun2017;8:1145 PMCID:PMC5658400

[31] Bolukbasi MF,Ozdener GB.miR-1289 and “Zipcode”-like sequence enrich mRNAs in microvesicles.Mol Ther Nucleic Acids2012;1:e10 PMCID:PMC3381601

[32] Supplee JG,Lim LP.Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.Lung Cancer2019;134:96-9

[33] Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271-82. PMCID:PMC7461630

[34] Drilon A, Siena S, Dziadziuszko R, et al; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261-70. PMCID:PMC7811790